REDEFINE is an ongoing phase 3 trial acting as market evaluation for both CagriSema and cagrilintide, with 60% randomised to CagriSema, 10% cagrilintide, 10% semaglutide, and 20% placebo, where minimum age at inclusion was 55 years with no upper limit [117]
Understanding how GLP-1 drugs affect your period provides context for these changes
Battery backup for GLP-1 storage is particularly valuable in areas experiencing grid instability, severe weather events, or planned power shutoffs
Depression affects a large proportion of the global population, but there are ways to mitigate the risk of this mental health condition
On April 1, the FDA approved Foundayo (orforglipron), Eli Lillys once-daily oral GLP-1 receptor agonist for obesity, which is the first oral GLP-1 approved for weight management and the fastest new molecular entity approval since 2002